Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27364707 | 0.98 | EPHX2 (0.40) | EPHX2SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL11164681 | 0.90 | SLC6A2 (0.33) | EPHX2SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL2555634 | 0.88 | CHRM1 (0.41) | EPHX2SLC6A2SLC6A4SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL3011881 | 0.86 | CHRM1 (0.40) | EPHX2SLC6A2SLC6A4SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL3011878 | 0.85 | CHRM1 (0.42) | EPHX2SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL27888454 | 0.84 | EPHX2 (0.46) | EPHX2ALDH1A1TSHR | |
| SCHEMBL27389747 | 0.82 | SLC6A4 (0.33) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL17309305 | 0.82 | SLC6A4 (0.33) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL15362827 | 0.82 | SLC6A4 (0.33) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL20133241 | 0.81 | EPHX2 (0.33) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380878-B1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO CO LTD (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2615089-A1 | PYRAZOLOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-07-17 | — | — | EP | disclosed |
| CN-102325754-A | Cyclic compound having hetero atom | DAIICHI SANKYO CO LTD | 2012-01-18 | — | — | CN | disclosed |
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| EP-2380878-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| US-4377581-A | ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4351940-A | Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4287341-A | USEFUL AS ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1981-09-01 | — | — | US | disclosed |
| EP-0028473-A1 | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them | PFIZER INC. (US) | 1981-05-13 | — | — | EP | disclosed |
| US-4237138-A | REGULATORS OF CARDIOVASCULAR SYSTEM | PFIZER INC. (US) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | BMP2, BMP4, BMP1 | EPHX2 2401/4885SLC6A2 577/4885SLC6A4 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.